Testosterone replacement therapy in patients with cachexia: a contemporary review of the literature

• Published in: Sexual medicine reviews Vol. 12; no. 3; pp. 469 - 476
• Main Authors: Tabei, Seyed Sajjad, Kataria, Rhea, Hou, Sean, Singh, Armaan, Al Hameedi, Hasan, Hasan, Doaa, Hsieh, Mike, Raheem, Omer A
• Format: Journal Article
• Language: English
• Published: Netherlands 26-06-2024
• Subjects: HIV; testosterone replacement therapy; TRT; cachexia; cancer cachexia; COPD
• ISSN: 2050-0513; 2050-0521; 2050-0521
• DOI: 10.1093/sxmrev/qeae031

Patients with long-term chronic illnesses frequently present with hypogonadism, which is primarily managed through exogenous testosterone. These same patients also experience a high degree of cachexia, a loss of skeletal muscle and adipose tissue.
To perform a contemporary review of the literature to assess the effectiveness of testosterone replacement therapy (TRT) for managing chronic disease-associated cachexia.
We performed a PubMed literature search using MeSH terms to identify studies from 2000 to 2022 on TRT and the following cachexia-related chronic medical diseases: cancer, COPD, HIV/AIDS, and liver cirrhosis.
From the literature, 11 primary studies and 1 meta-analysis were selected. Among these studies, 3 evaluated TRT on cancer-associated cachexia, 3 on chronic obstructive pulmonary disease, 4 on HIV and AIDS, and 2 on liver cirrhosis. TRT showed mixed results favoring clinical improvement on each disease.
Cachexia is commonly observed in chronic disease states. Its occurrence with hypogonadism, alongside the shared symptoms of these 2 conditions, points toward the management of cachexia through the administration of exogenous testosterone. Robust data in the literature support the use of testosterone in increasing lean body mass, improving energy levels, and enhancing the quality of life for patients with chronic disease. However, the data are variable, and further studies are warranted on the long-term efficacy of TRT in patients with cachexia.